ArticleDiscover oncology2025
The causal relationship between platelet indices and liver cancer: a bidirectional two-sample Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPlatelet indices are non-invasive biomarkers used to assess disease status. Observational studies have shown that platelet indices are related to liver cancer. However, the specific relationship between the two is still inconclusive. We conducted a Mendelian randomization (MR) study to investigate the causal relationship between platelet indices and liver cancer.
methodsWe identified 2 cancer outcomes (liver cell carcinoma, malignant neoplasm of liver and intrahepatic bile ducts) from genome-wide association studies (GWAS). We used inverse variance weighted (IVW) method as the main method. In order to evaluate the potential horizontal pleiotropy or heterogeneity, sensitivity analyses were examined via MR-Egger regression, heterogeneity test, pleiotropy test.
resultsTwo-Sample MR analysis showed there were causal relationships between platelet indices and liver cancer. The mean platelet volume was positively associated with hepatocellular carcinoma (HCC) risk, while platelet count was inversely correlated with HCC risk, platelet endothelial cell adhesion molecule levels were significantly related to an increased malignant neoplasm of liver and intrahepatic bile ducts risk. In addition, we conducted reverse MR analyses and found that malignant neoplasm of liver and intrahepatic bile ducts was positively associated with platelet count and platelet crit, but negatively correlated with platelet distribution width. Following multivariable mendelian randomization adjustments for potential confounding variables, the independent effects of platelet indices on HCC were not statistically significant.
conclusionsThe bidirectional causal relationship between platelet indices and liver cancer may be mediated by confounding factors such as liver cirrhosis. Further validation through mediation MR analyses or larger-scale replication studies is required to elucidate these causal pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.